NCT06020885Active, not recruitingPhase 1
Fraction Dose Escalation of Split-course Hypofractionated Concurrent Chemoradiotherapy Following Induction Chemo-immunotherapy in Unresectable Locally Advanced Esophageal Squamous Carcinoma: a Phase I Study.
Source: ClinicalTrials.gov · Last updated 21 Jul 2025
Brief summary (registry, in English)
This Phase I study is to determine the maximum tolerated fraction dose (MTD) for split-course hypo-CCRT following induction chemo-immunotherapy in LA-ESCC patients, to clarify the dosimetric advantage of split-course hypo-CCRT, and to investigate the treatment-related toxicities and quality of life of the new regimen.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- First submitted
- 26 Aug 2023
- Start date
- 31 Aug 2023
- Primary completion date
- 30 Oct 2025
- Lead sponsor
- Sun Yat-sen University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06020885
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 18
- From 31 Aug 2023 to the primary completion date, 30 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- contraindication for radiotherapy or chemotherapy
Other illness
- prior malignancies, except for curable non-melanoma skin cancer or cervical carcinoma in situ
Other
- distant metastasis, except for celiac or supraclavicular lymph nodes metastases
Who the study is looking for
- histologically confirmed ESCC
- II-IVB stages (IVB stage only with metastatic celiac or supraclavicular lymph nodes) based on the TNM staging system proposed by the International Union Against Cancer (UICC 2002)
- Eastern Cooperative Oncology Group (ECOG) performance status score 0-1
- Charlson Comorbidity Index score≤4
- oral medication can be administered despite esophageal obstruction
- adequate hematological, renal and hepatic functions
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sun Yat-sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.